Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring  by Bolhuis, Mathieu S. et al.
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y x x x ( 2 0 1 6 ) x x x –x x x
.sc ienced i rec t .comAvai lab le a t wwwScienceDirect
journal homepage: www.elsevier .com/ locate / IJMYCOIndividualized treatment of multidrug-resistant
tuberculosis using therapeutic drug monitoringhttp://dx.doi.org/10.1016/j.ijmyco.2016.07.003
* Corresponding author at: University of Groningen, University Medical Center Groningen, Department of Clinical Phar
Pharmacology, PO Box 30.001, 9700 RB Groningen, The Netherlands.
E-mail address: m.s.bolhuis@umcg.nl (M.S. Bolhuis).
Peer review under responsibility of Asian African Society for Mycobacteriology.
Please cite this article in press as: MS Bolhuis et al. Individualized treatment of multidrug-resistant tuberculosis using therapeutic dru
ing. Int. J. Mycobacteriol. (2016), http://dx.doi.org/10.1016/j.ijmyco.2016.07.003Mathieu S. Bolhuis a,*, Onno W. Akkerman b, Marieke G.G. Sturkenbooma,
Wiel C.M. de Lange b, Tjip S. van der Werf b,c, Jan-Willem C. Alffenaara
aUniversity of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen,
The Netherlands
b University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen,
The Netherlands
cUniversity of Groningen, University Medical Center Groningen, Department of Internal Medicine, Groningen, The NetherlandsA R T I C L E I N F O
Article history:
Received 30 June 2016
Accepted 11 July 2016
Available online xxxxA B S T R A C T
Objective/Background: Globally, approximately 50% of patients with multidrug-resistant
tuberculosis (MDR-TB) experience treatment failure. MDR-TB treatment is hindered by
adverse events, toxicity of the second-line anti-TB drugs, logistics and costs, especially in
low-income countries, and problems with medication adherence. Pharmacokinetic vari-
ability is also attributed as one of the reasons contributing to treatment failure. In our ref-
erence Tuberculosis Center Beatrixoord (University Medical Center Groningen, Groningen,
The Netherlands), we strive to individualize treatment of all MDR-TB patients based on
drug-susceptibility testing using minimal inhibitory concentrations and pharmacokinetic
parameters. The aim of this work is to give an overview of our efforts to individualize treat-
ment of MDR-TB patients and to provide insights into practical tools that might be imple-
mented in other clinical settings worldwide.
Methods: We critically looked at clinical practice guidelines implemented in our center to
give an overview of practically applied tools to individualize treatment of MDR-TB patients.
Furthermore, we selected studies carried out in our clinic on treatment individualization of
MDR-TB patients and combined their results with recent studies in this area to suggest
practical tools for implementation in other clinical settings.
Results: We regularly perform therapeutic drug monitoring (TDM) of several second-line
anti-TB drugs, such as amikacin, kanamycin, linezolid, and moxifloxacin. New analyses
of Group D and experimental drugs, such as co-trimoxazole (sulfamethoxazole/trimetho
prim), bedaquiline, delamanid, and clarithromycin, have been or are being developed. By
implementing TDM methods, variability in pharmacokinetics is often detected and treat-
ment is adjusted, possibly preventing toxicity in patients with very high drug exposure
or treatment failure, or resistance in patients with very low drug exposure. Over the past
10 years in the Netherlands, 86% of 104 patients had a successful outcome using a median
of six active drugs. Many studies were performed using dried blood spot (DBS) analysis of
second-line TB drugs. These studies may be used to implement TDM worldwide, even in
low-income countries. Furthermore, several studies are performed to determine limitedmacy and
g monitor-
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pling, TDM will become easier to implement. Other examples of LSSs included develop-
ment of oral fluid sampling methods or development of semiquantitative thin-layer
chromatography methods.
Conclusion: TDM is highly valuable to individualize and optimize treatment of complex
MDR-TB patients. TDM is routinely applied in Tuberculosis Center Beatrixoord, and high
success rates for treatment of MDR-TB patients have been achieved. DBS and LSS make
implementation of TDM feasible, even in low- and middle-income countries.Conflicts of interest
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